useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established

Kidney injury molecule 1 (KIM-1): A potential biomarker of acute kidney injury and tubulointerstitial injury in patients with ANCA-glomerulonephritis
optional cycling with 6-week breaks between courses
However, at pharmacological concentrations GLP-1, but not GIP, reduces appetite and prospective food intake and increases satiety
Bone marrow diseases , such as blood cancer that suppress red blood cell function and production, such as multiple myeloma, leukemia, aplastic anemia, myelodysplastic syndrome, or bone marrow infection